| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Christopher Bishop, Jessica A George, William Buchta, Adam A Goldenberg, Mohamed Mohamed, Sando O Dickinson, Satie Eissa, Karen L Eskow Jaunaraj. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. The European journal of neuroscience. vol 36. issue 6. 2013-01-09. PMID:22762478. |
therefore, in the current study, selective serotonin reuptake inhibitors were tested for their ability to reduce l-dopa- and apomorphine-induced dyskinesia. |
2013-01-09 |
2023-08-12 |
rat |
| Christopher Bishop, Jessica A George, William Buchta, Adam A Goldenberg, Mohamed Mohamed, Sando O Dickinson, Satie Eissa, Karen L Eskow Jaunaraj. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. The European journal of neuroscience. vol 36. issue 6. 2013-01-09. PMID:22762478. |
in experiment 2, dyskinesias were measured after selective serotonin reuptake inhibitors and apomorphine. |
2013-01-09 |
2023-08-12 |
rat |
| B D Scheepers, D G Roger. Dyskinesias following treatment with 5-HT re-uptake inhibitors. Journal of psychopharmacology (Oxford, England). vol 8. issue 4. 2012-10-02. PMID:22298632. |
dyskinesias following treatment with 5-ht re-uptake inhibitors. |
2012-10-02 |
2023-08-12 |
Not clear |
| Daniella Rylande. The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery. Parkinsonism & related disorders. vol 18 Suppl 1. 2012-08-27. PMID:22166409. |
furthermore, serotonin can influence dyskinesia by modulating glutamate or gaba signalling in the basal ganglia via receptors located on non-serotonergic neurons. |
2012-08-27 |
2023-08-12 |
Not clear |
| Eunju Shin, Elisabetta Tronci, Manolo Cart. Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease. Parkinson's disease. vol 2012. 2012-08-23. PMID:22762012. |
role of serotonin neurons in l-dopa- and graft-induced dyskinesia in a rat model of parkinson's disease. |
2012-08-23 |
2023-08-12 |
rat |
| Perdita A Cheshire, David R William. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 19. issue 3. 2012-05-31. PMID:22249009. |
here, we review the evidence for serotonergic involvement in dyskinesias from animal and human data, and highlight some of the translational gaps which may explain why the success of serotonin autoreceptor agonists as anti-dyskinetic agents in experimental models has failed to be replicated in clinical trials. |
2012-05-31 |
2023-08-12 |
human |
| Corinne Y Ostock, Kristin B Dupre, Karen L Eskow Jaunarajs, Hannah Walters, Jessica George, David Krolewski, Paul D Walker, Christopher Bisho. Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. Neuropharmacology. vol 61. issue 4. 2012-05-25. PMID:21635907. |
while serotonin 5-ht1a receptor (5-ht1ar) agonists reduce l-dopa-induced dyskinesias (lid) by normalizing activity in the basal ganglia neurocircuitry, recent evidence suggests putative 5-ht1ar within the primary motor cortex (m1) may also contribute. |
2012-05-25 |
2023-08-12 |
rat |
| Joanna García, Thomas Carlsson, Máté Döbrössy, Guido Nikkhah, Christian Winkle. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia. Neurobiology of disease. vol 43. issue 3. 2012-05-21. PMID:21600983. |
impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and l-dopa-induced dyskinesia. |
2012-05-21 |
2023-08-12 |
rat |
| Joanna García, Thomas Carlsson, Máté Döbrössy, Guido Nikkhah, Christian Winkle. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia. Neurobiology of disease. vol 43. issue 3. 2012-05-21. PMID:21600983. |
recently, the inclusion of serotonin (5-ht) neurons in the grafted tissue has been suggested to play an important negative role, in particular, on the effect of l-dopa-induced dyskinesia. |
2012-05-21 |
2023-08-12 |
rat |
| Joanna García, Thomas Carlsson, Máté Döbrössy, Guido Nikkhah, Christian Winkle. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia. Neurobiology of disease. vol 43. issue 3. 2012-05-21. PMID:21600983. |
in the present study we have evaluated the influence of different ratios of da neurons in relation to 5-ht neurons in the graft on spontaneous motor behavior and l-dopa-induced dyskinesia in a rat model of parkinson's disease. |
2012-05-21 |
2023-08-12 |
rat |
| Joanna García, Thomas Carlsson, Máté Döbrössy, Guido Nikkhah, Christian Winkle. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia. Neurobiology of disease. vol 43. issue 3. 2012-05-21. PMID:21600983. |
increasing the ratio of 5-ht neurons in the graft, to a da:5-ht ratio of in between 1:3 and 1:10, still induces significant reduction of l-dopa-induced dyskinesia, suggesting that the detrimental effect of 5-ht neurons on l-dopa-induced dyskinesia is prevented even by small numbers of da neurons in the graft. |
2012-05-21 |
2023-08-12 |
rat |
| Manfred Gerlach, Gerd D Bartoszyk, Peter Riederer, Olivia Dean, Maarten van den Buus. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996). vol 118. issue 12. 2012-03-30. PMID:21253782. |
role of dopamine d3 and serotonin 5-ht 1a receptors in l: -dopa-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of parkinson's disease. |
2012-03-30 |
2023-08-12 |
rat |
| Philippe Huot, Tom H Johnston, Lieke Winkelmolen, Susan H Fox, Jonathan M Brotchi. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiology of aging. vol 33. issue 1. 2012-03-13. PMID:20561716. |
moreover, 5-ht(2a) receptor antagonists can reduce l-dopa-induced dyskinesia (lid). |
2012-03-13 |
2023-08-12 |
Not clear |
| Philippe Huot, Tom H Johnston, Lieke Winkelmolen, Susan H Fox, Jonathan M Brotchi. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiology of aging. vol 33. issue 1. 2012-03-13. PMID:20561716. |
we hypothesized that enhanced 5-ht(2a)-mediated neurotransmission may be involved in the genesis of l-dopa-induced dyskinesia. |
2012-03-13 |
2023-08-12 |
Not clear |
| Philippe Huot, Tom H Johnston, Lieke Winkelmolen, Susan H Fox, Jonathan M Brotchi. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiology of aging. vol 33. issue 1. 2012-03-13. PMID:20561716. |
radioligand binding autoradiography, using [(3)h]-ketanserin, was performed to define 5-ht(2a) receptor levels in brain tissue from macaques: 6 normal; 5 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp)-lesioned, parkinsonian macaques, without exposure to l-dopa; 6 mptp-lesioned, parkinsonian macaques, receiving a single administration of l-dopa, and exhibiting no dyskinesia; and 6 mptp-lesioned, parkinsonian, macaques chronically treated with l-dopa, and exhibiting dyskinesia. |
2012-03-13 |
2023-08-12 |
Not clear |
| Philippe Huot, Tom H Johnston, Lieke Winkelmolen, Susan H Fox, Jonathan M Brotchi. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiology of aging. vol 33. issue 1. 2012-03-13. PMID:20561716. |
these data provide an anatomical basis for mechanisms to explain the efficacy of 5-ht(2a) antagonists against dyskinesia. |
2012-03-13 |
2023-08-12 |
Not clear |
| Philippe Huot, Tom H Johnston, James B Koprich, Lieke Winkelmolen, Susan H Fox, Jonathan M Brotchi. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiology of aging. vol 33. issue 1. 2012-03-13. PMID:21051107. |
serotonergic 1a (5-ht(1a)) receptor agonists reduce l-3,4-dihydroxyphenylalanine (l-dopa)-induced dyskinesia in parkinson's disease (pd), though the mechanism(s) and site(s) of action remain unclear. |
2012-03-13 |
2023-08-12 |
monkey |
| Philippe Huot, Tom H Johnston, James B Koprich, Lieke Winkelmolen, Susan H Fox, Jonathan M Brotchi. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiology of aging. vol 33. issue 1. 2012-03-13. PMID:21051107. |
we employed [(3)h]-way 100,635 autoradiographic receptor binding to measure 5-ht(1a) receptor levels in 4 groups of macaques: normal (vehicle-vehicle); 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp)-lesioned, without exposure to l-dopa, i.e., untreated parkinsonian (mptp-vehicle); mptp-lesioned, receiving a single administration of l-dopa to alleviate parkinsonism (mptp-l-dopa-acute); and mptp-lesioned, chronically treated with l-dopa, parkinsonism alleviated but exhibiting dyskinesia (mptp-l-dopa-chronic). |
2012-03-13 |
2023-08-12 |
monkey |
| Marios Politis, Wolfgang H Oertel, Kit Wu, Niall P Quinn, Oliver Pogarell, David J Brooks, Anders Bjorklund, Olle Lindvall, Paola Piccin. Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Movement disorders : official journal of the Movement Disorder Society. vol 26. issue 11. 2012-01-27. PMID:21611977. |
inhibition of serotonin neuron activity by systemic administration of a 5-ht(1a) agonist suppressed graft-induced dyskinesias. |
2012-01-27 |
2023-08-12 |
Not clear |
| Philippe Huot, Susan H Fox, Adrian Newman-Tancredi, Jonathan M Brotchi. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? The Journal of pharmacology and experimental therapeutics. vol 339. issue 1. 2011-11-22. PMID:21784889. |
serotonergic type 1a (5-ht(1a)) receptor agonists and serotonergic type 2a (5-ht(2a)) receptor antagonists were, until recently, considered to be promising therapies against dyskinesia. |
2011-11-22 |
2023-08-12 |
Not clear |